Abstract
Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Central Nervous System Agents in Medicinal Chemistry
Title:Genetics in Neural Toxicities of Drugs
Volume: 12 Issue: 4
Author(s): Da-Yong Lu, Ting-Ren Lu and Peng-Peng Zhu
Affiliation:
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Abstract: Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren and Zhu Peng-Peng, Genetics in Neural Toxicities of Drugs, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/187152412803760591
DOI https://dx.doi.org/10.2174/187152412803760591 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Current Pharmaceutical Design Pharmacotherapy and the Psychobiological Model of Personality: Implications for DSM-5
Current Psychopharmacology Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine In memory of Prof. Stephen Drake Skaper
CNS & Neurological Disorders - Drug Targets Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease Drugs- In Vitro Comparison of Cholinesterase Inhibition and beta-amyloid Modulation
Letters in Drug Design & Discovery Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD
Current Alzheimer Research Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application
Current Neuropharmacology Endocannabinoids and Drug Dependence
Current Drug Targets - CNS & Neurological Disorders Roles for Serotonin in Neurodevelopment: More than just Neural Transmission
Current Neuropharmacology Central and Peripheral Expression and Distribution of NUCB2/nesfatin-1
Current Pharmaceutical Design New Tuberculosis Drugs in Development
Current Topics in Medicinal Chemistry